HIGHLIGHTS
- who: Zhitao Ying and collaborators from the Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital and Institute, Beijing, China have published the paper: Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis, in the Journal: (JOURNAL)
- what: Literature Search This systematic review and meta-analysis was conducted in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et_al, 2009). The following . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.